A little java reduces mortality risk in CRC

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • For patients with colorectal cancer (CRC), drinking just 2 cups of coffee per day reduces CRC-specific mortality risk by 39%, and drinking 4 cups/day reduces risk by 52%.

Why this matters

  • Although there are some data to suggest a protective effect of coffee against CRC, it was unknown if coffee consumption after diagnosis offered any protection against recurrence or mortality.

Study design

  • 1599 people with stage I-III CRC from the Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS).
  • Median follow-up 7.8 years.
  • Funding: NIH and others.

Key results

  • 803 deaths during study period, including 188 CRC-related.
  • 52% lower risk of CRC-specific mortality (HR, 0.48; 95% CI: 0.28-0.83) and 30% lower risk of all-cause mortality (HR, 0.70; 95% CI: 0.54-0.91) among patients who drank ≥4 cups/day vs those who didn’t drink any coffee; similar rates for caffeinated and decaffeinated.
  • Drinking ≥2 cups/day associated with a 39% lower risk of CRC-specific mortality (RR, 0.61: 95% CI: 0.40-0.91 for caffeinated and RR, 0.061; 95% CI, 0.38-0.97 for decaffeinated) and a 25% lower all-cause mortality risk for caffeinated (RR, 0.75; 95% CI: 0.62-0.91) and 30% for decaffeinated (RR, 0.70; 95% CI: 0.55-0.87).

Limitations

  • No data on cancer recurrence and coffee intake.